Phibro Animal Health closed out fiscal 2026 with full-year net sales topping $1.5 billion, adjusted EBITDA climbing 39% to $255 million, and adjusted diluted earnings per share jumping 48% to $3.22, marking the first complete fiscal year since folding in a large medicated feed additive portfolio. The acquired feed additive business grew 70% for the full year and added $354.3 million in sales, while the Animal Health segment overall rose 21% to $1.162 billion, Mineral Nutrition climbed 11% to $282.3 million, and vaccine sales rose 14% to $156.4 million. However, free cash flow came in at just $9.9 million due to an $86.3 million inventory buildup, leaving total debt at $737.9 million and gross leverage at 2.9 times EBITDA. Guidance for fiscal 2027 calls for net sales of $1.55 billion to $1.6 billion and adjusted EBITDA of $258 million to $268 million, a sharp step down from this year's pace, with regulatory uncertainty in Brazil and the Chicago Heights plant closure adding further headwinds. Hedge fund ownership fell from 24 funds to 17 funds, and short interest sits at 6.96% of float, suggesting the market is still pricing in the acquisition's full impact.
Phibro Animal Health CorporationStrong full-year results with sales topping $1.5B, EBITDA up 39%, EPS up 48%, and acquired feed additive business growing 70%.
